Binnopharm Group Launched New Suppository Line at the Binnopharm Manufacturing Site in Zelenograd


As part of its manufacturing sites modernization program, Binnopharm Group, a leading Russian pharmaceutical company, has launched a new suppository production line at the Binnopharm site in Zelenograd. The new automated suppository line has a production capacity of 15,000 suppositories per hour.

The Company plans to manufacture 3 medicinal products for different diseases on the suppository line. Currently, production of pilot scale batches on the line has been completed, and commercial production of Venaproct, a new product for the Binnopharm site, has been launched. The product will be available in pharmacies at the end of the Q2 of this year.

Two more products in a convenient marketable suppository packaging will be put into production by the end of 2024.

Anatoly Yaglenko, Corporate Operations Director, explains: «In 2023, our site in Zelenograd has increased its production capacity to 7.3 million packages. The plant is developing, product portfolio is expanding and production plans are growing. With the launch of the new line, the Company intends to increase production and sales volume of suppository products. Moreover, the plant is ramping up production of other dosage forms: aerosols, ampoules, and solid dosage forms».